1507P - Pembrolizumab (PEM) in patients with advanced/metastatic bone sarcoma (BS) or soft tissue sarcoma (STS): named patient use by the Medical Universit...

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Bone Sarcomas
Soft Tissue Sarcomas
Cancer Immunology and Immunotherapy
Presenter Sophie Schur
Citation Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387
Authors S. Schur1, T. Brodowicz1, B. Gad1, R. Hamacher1, G. Amann2, S. Lang2
  • 1Clinical Division Of Oncology, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 2Department Of Pathology, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT



Treatment options in locally advanced/metastatic BS and STS are limited. PEM has shown first signs of promising activity in some histologic subtypes. In this named patient use BS and STS patients who either failed standard therapy or where no standard therapy was established were treated with PEM.


This retrospective analysis includes efficacy/safety data from 18 pts. with advanced/metastatic BS/STS treated with PEM 200mg d1, q21d between May 2016 and April 2017.


10 pts. were female (56%), 8 pts. male (44%). Median age was 45 yrs. (range 18-84 yrs.). Extent of disease at initial diagnosis was localized in 15 pts. (83%) and advanced/metastatic in 3 pts. (17%). The median number of previous lines of systemic treatment before PEM was 3 (range 0-7 lines). In total, 71 cycles of PEM were administered (median 3 cycles per pt., range 1-11 cycles). Immune-related side effects were hypothyroidism in two pts. and uveitis in one pt. PD-L1 assessment on tumor samples is ongoing.Table:


patient IDhistologyn PEM cyclesstatusstatus PEM
1fibromyxoid sarcoma4*1
2OSA1100 NED
4myxofibrosarcoma800 PR
7dedifferentiated LPS700 PR
10chondrosarcoma500 SD
11myxoid LPS300 PR
13dedifferentiated LPS500 SD
14synovialsarcoma300 SD
15epitheloid sarcoma300 PR
16OSA200 ie
17OSA300 ie
18myxoid LPS200 ie

Abbreviation: OSA = osteosarcoma, EMC = extraskeletal myxoid chondrosarcoma, LPS = liposarcoma, status 0 = alive, * = dead; status PEM 0 = PEM ongoing, 1 = PEM discontinued to PD (progressive disease); NED = no evidence of disease, PR = partial remission, SD = stable disease, ie = response in evaluation.


In this unselected cohort, PEM seems to have some activity in advanced/metastatic BS/STS. However, longer follow up of treated patients and prospective clinical trials of PEM in BS/STS patients will define the value of PEM in this patient cohort. Updated efficacy and toxicity data as well as PD-L1 expression levels will be presented at the meeting.

Clinical trial identification

Legal entity responsible for the study

Thomas Brodowicz, Clinical Division of Oncology, Medical University of Vienna




S. Schur: Personal fees from Eli Lilly (advisory board) outside the submitted work. T. Brodowicz: Personal fees from Roche and PharmaMar for lecture fees and from Amgen, Bayer, Novartis, Eisai and Eli Lilly for lecture fees and advisory boards. All other authors have declared no conflicts of interest.